SEC Form 4 · accession 0001349929-17-000015
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Igor Gitelman
Officer — Chief Accounting Officer
Period of report
Feb 22, 2017
Accepted (ET)
Feb 24, 2017 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.50 | Feb 22, 2017 | A | 15,000 | A | — | Feb 22, 2027 | Common Stock, par value $0.0001 per share | 15,000 | 15,000 | D |
Explanation of responses
- F1The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period.